Biomarkers of Cancer-Associated Myositis
Key facts
- Who runs it
- Azienda USL Reggio Emilia - IRCCS
- Where
- Italy2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 50 people enrolled
- Started
- 13 Jun 2019
- Expected to end
- 31 Dec 2026
- Type of study
- Observational, 3 groups
- Record updated
- 5 May 2026
Who can take part
- Age
- 40 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age > 40 years
- Diagnosis of DM
- Informed Consent
Who cannot take part
- Chemotherapy at the time of the peripheral venous blood draw
- Therapy with biologic drugs at the time of the peripheral venous blood draw
- Necrotizing autoimmune myopathy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The project is about dermatomyositis (DM), an autoimmune disease characterized by inflammation in the skeletal muscles and skin. Patients with DM have an increased risk of cancer, with a cancer incidence between 5.5% and 42%. Cancers in these patients are one of the leading causes of death. Some myositis-specific autoantibodies have been discovered and some of them are associated with cancer development. However, DM patients negative for all the known autoantibodies can also develop cancer. The Investigator hypothesized that antibodies against plasma membrane antigens and soluble immune checkpoints can be responsible for the association between cancers and autoimmunity. Therefore, the present study aimed to identify novel antigens and immunological pathways in patients with DM with cancer versus patients with DM without cancer, to identify those patients who need cancer screening. The Investigators focus on soluble immune checkpoint molecules and autoantibodies directed against plasma membrane antigens.
The 3 groups in the trial
- DM without cancer
Patients with DM who do not have cancer at diagnosis and in the 3-year follow-up period
- DM with cancer
Patients with DM who have cancer at diagnosis or in the 3-years before or after DM diagnosis
- Healthy controls
Subjects without known cancer, autoimmune diseases and infections
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Plasma Membrane Antigens as Trigger in Cancer-associated Myositis
- Record updated
- 5 May 2026